Payment overview · 2025
General Payments
$805.22
10 reported records · 8 companies
Healthcare provider profile · identity verified
Catherine A Obin, ANCC
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · WAREHAM, MA · NPI 1841286739
Verified facts
What the public records show
CMS Open Payments records show Catherine A Obin, ANCC received $805.22 in general payments during 2025 across 10 reported records.
AstraZeneca Pharmaceuticals LP accounted for 18.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $148.20 | 18.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $124.99 | 15.5% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $120.23 | 14.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $106.12 | 13.2% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $100.50 | 12.5% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $83.82 | 10.4% | 1 | 2025 |
| Calliditas Therapeutics US Inc. | Unresolved — no canonical attribution shown | $71.41 | 8.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $49.95 | 6.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $755.27 | 9 |
| Long term medical supply or device loan | $49.95 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $148.20 | 3 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $120.23 | 1 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $106.12 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $100.50 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $83.82 | 1 | 2025 |
Source payment records
|
|||||
| TARPEYO Normalized: tarpeyo |
Drug | Calliditas Therapeutics US Inc. | $71.41 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE INSULINX Normalized: freestyle insulinx |
Device | Abbott Laboratories | $49.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 165 | 56 |
| Amlodipine Besylate | Amlodipine Besylate | 148 | 46 |
| Atorvastatin Calcium | Atorvastatin Calcium | 137 | 51 |
| Levothyroxine Sodium | Levothyroxine Sodium | 126 | 38 |
| Lisinopril | Lisinopril | 113 | 37 |
| Lorazepam | Lorazepam | 112 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 104 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 103 | 36 |
| Sertraline Hcl | Sertraline Hcl | 83 | 23 |
| Gabapentin | Gabapentin | 81 | 17 |
| Trazodone Hcl | Trazodone Hcl | 78 | 23 |
| Metformin Hcl | Metformin Hcl | 76 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 65 | 26 |
| Losartan Potassium | Losartan Potassium | 63 | 19 |
| Prednisone | Prednisone | 58 | 43 |
| Tramadol Hcl | Tramadol Hcl | 57 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 52 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 51 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 50 | 17 |
| Metformin Hcl Er | Metformin Hcl | 46 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 45 | 17 |
| Mirtazapine | Mirtazapine | 40 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 39 | 13 |
| Famotidine | Famotidine | 38 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 38 | suppressed |
| Irbesartan | Irbesartan | 37 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | suppressed |
| Atenolol | Atenolol | 35 | 11 |
| Furosemide | Furosemide | 35 | 14 |
| Trulicity | Dulaglutide | 35 | suppressed |
| Alprazolam | Alprazolam | 34 | suppressed |
| Ibuprofen | Ibuprofen | 32 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Simvastatin | Simvastatin | 32 | 13 |
| Eliquis | Apixaban | 31 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 31 | 11 |
| Allopurinol | Allopurinol | 30 | 11 |
| Jardiance | Empagliflozin | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 28 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 23 | suppressed |
| Ozempic | Semaglutide | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Meloxicam | Meloxicam | 22 | 11 |
| Potassium Chloride | Potassium Chloride | 22 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Azithromycin | Azithromycin | 20 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Zaleplon | Zaleplon | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $805.22 · 10 records | AstraZeneca Pharmaceuticals LP | APTIMA, BREZTRI, FREESTYLE INSULINX, NEFFY, RINVOQ, TARPEYO, TZIELD | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error